<i id='CB34AFB7B3'><strike id='CB34AFB7B3'><tt id='CB34AFB7B3'><pre id='CB34AFB7B3'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Wildfire smoke exposes gaps in outdoor worker protections 
ARCH Venture Partners tops STAT's 2023 biotech VC rankings 
23andMe had bad news about my health. I wish a person had delivered it 
At Orexo, a ‘turning point’ for everything but digital health 
Apple is now the first public company to be valued at $3 trillion 
Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine 
Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies 
Why hospitals are withdrawing from US News rankings 
Bright Health sells Medicare Advantage business to Molina 
Where does female orgasm come from? Scientists think they know 
DIEP, the 'gold standard' of breast reconstruction, is under threat 
WHO calls for emergency meeting on new China virus, as cases spread 
As demand for Covid shots wanes, Moderna seeks its next success 
EHR maker NextGen Healthcare to pay $31M to resolve fraud claims 
State Dept. review finds Biden bears some blame for Afghanistan failures 
